Full text is available at the source.
Abstract
Gastroparesis is an under-recognised complication of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for type 2 diabetes and obesity.
- Gastrointestinal adverse effects are common with GLP-1RA treatment.
- Gastroparesis is associated with the use of GLP-1RAs, though it is not widely acknowledged.
- The systematic review examines the presentation, diagnosis, management, and outcomes of gastroparesis in clinical settings.
Simplified